Epigenomics AG Profit Margin

The latest profit margin for ECX.F is -1288.36% as of September 2022. That compares with -51.7% in the prior-year period — down 2392.0% year over year. That is below the sector sector average of 13.2%. Investors often review this figure alongside Epigenomics AG's historical trend and sector peers before judging valuation or financial health.

Over the past year, ECX.F's profit margin moved from -51.7% to -1288.36% — a 2392.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Epigenomics AG's valuation or profitability profile.

Against its sector companies, ECX.F currently prints -1288.36% for profit margin, while the sector average sits near 13.2%. That is roughly 9861.1% below the sector mean. Large gaps often invite a closer look at Epigenomics AG's growth, margins, and balance sheet.

Profit Margin shows how effectively Epigenomics AG converts resources into returns. At -1288.36%, ECX.F may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -51.7% in the prior-year period — down 2392.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ECX.F's profit margin (-1288.36%), review year-over-year change from -51.7%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.